Home › Funds › Cormorant Asset Management, LP › MBX

Cormorant Asset Management, LP position in MBX

MBX BIOSCIENCES INC COM · Health Care

Cormorant Asset Management, LP reported holding 550,000 shares of MBX (MBX BIOSCIENCES INC COM) in its Q2 2026 13F filing — a position valued at US$30.4M, representing 1.56% of its reported portfolio and ranking #20 among its reported holdings. Cormorant Asset Management, LP has disclosed MBX holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

Latest position (Q2 2026)550.00K sh
Reported value held$30.36M
Portfolio Weight1.56%
First reportedQ3 2024
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Cormorant Asset Management, LP's MBX position evolved

Cormorant Asset Management, LP first disclosed a stake in MBX in Q3 2024 at 700,000 shares (US$18.2M). The position peaked in Q4 2025 at 1,120,000 shares, worth US$35.3M. Across 8 filings, Cormorant Asset Management, LP increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 550,000 shares valued at US$30.4M — a reduction of -570,000 shares quarter over quarter.. Notable position changes include a 75% increase in Q3 2025 (shares rose 80% over the following quarter), a 51% trim in Q2 2026 (shares rose 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2024 700.00K $18.19M New
Q4 2024 700.00K $12.90M Hold
Q1 2025 700.00K $5.17M Hold
Q2 2025 700.00K $7.99M Hold
Q3 2025 1.23M $21.44M Add
Q4 2025 1.12M $35.32M Reduce
Q1 2026 1.12M $33.43M Hold
Q2 2026 550.00K $30.36M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MBX and 13F data

MBX (MBX BIOSCIENCES INC COM) is a Health Care company. 73 other funds we track also report a position in MBX — the largest reported positions include Frazier Life Sciences Management, L.P. (US$367.2M), NEA Management Company, LLC (US$199.5M), ORBIMED ADVISORS LLC (US$189.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MBX

All MBX fund holders →

FAQ

How long has Cormorant Asset Management, LP held MBX?

Cormorant Asset Management, LP has disclosed MBX holdings in 8 of the last 8 reported quarters, going back to Q3 2024.

What is Cormorant Asset Management, LP's current position in MBX?

As of Q2 2026, Cormorant Asset Management, LP holds 550.00K shares of MBX (MBX BIOSCIENCES INC COM), valued at $30.36M, representing 1.56% of its reported portfolio and ranking #20.

Has Cormorant Asset Management, LP been buying or selling MBX?

In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP reduced its position in MBX. The position peaked in Q4 2025 at 1.12M shares.

Which other funds hold MBX?

Other major institutional holders of MBX include Frazier Life Sciences Management, L.P., NEA Management Company, LLC, ORBIMED ADVISORS LLC, among 73 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.